CJ Bioscience KRX:311690KOSDAQ
CJ 바이오사이언스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, CJ Bioscience reported revenue of ₩898m, up 14.6% year on year, and an operating loss of ₩6.4bn. CJ Bioscience (CJ 바이오사이언스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
CJ Bioscience quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩898m | +14.6% | −₩6.4bn | −₩6.2bn |
| Q1 2026 | ₩783m | -14.2% | −₩5.3bn | −₩5.1bn |
| Q4 2025 derived | ₩1.3bn | +33.7% | −₩5.2bn | −₩5.2bn |
| Q3 2025 | ₩738m | -0.8% | −₩6.1bn | −₩5.8bn |
| Q2 2025 | ₩784m | +0.9% | −₩7.0bn | −₩6.9bn |
| Q1 2025 | ₩913m | -9.1% | −₩6.6bn | −₩6.1bn |
| Q4 2024 derived | ₩941m | -34.7% | −₩9.8bn | −₩9.5bn |
| Q3 2024 | ₩744m | -55.6% | −₩8.6bn | −₩8.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
CJ Bioscience top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest CJ Bioscience news Korean headlines
No articles yet.